Biotest AG (HAM:BIO) Scaled Net Operating Assets: 0.31 (As of Mar. 2025)


HAM:BIO Biotest AG HAM:BIO
56 GF Score
Price €40.00
View Full Analysis

What is Biotest AG Scaled Net Operating Assets?

Biotest AG HAM:BIO +2.04% 56 Scaled Net Operating Assets is 0.31 as of Mar. 2025. GuruFocus rates HAM:BIO with a GF Score™ of 56/100.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Biotest AG's operating assets for the quarter that ended in Mar. 2025 was €1,356.7 Mil. Biotest AG's operating liabilities for the quarter that ended in Mar. 2025 was €906.9 Mil. Biotest AG's Total Assets for the quarter that ended in Dec. 2024 was €1,434.0 Mil. Therefore, Biotest AG's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2025 was 0.31.

Biotest AG Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Biotest AG's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest AG Scaled Net Operating Assets Chart

Biotest AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.74 0.67 0.73 0.83 0.72

Biotest AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.31 0.36 0.75 0.31

HAM:BIO vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Biotest AG's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotest AG Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Biotest AG's Scaled Net Operating Assets falls into.


HAM:BIO
56GF Score
Biotest AG HAM:BIO
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biotest AG Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Biotest AG's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(1314.5-306.1)/1410.9
=0.71

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1434 - 119.5
=1314.5

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=903.3 - 591.5 - 5.7
=306.1

Biotest AG's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2025 )
=(Operating Assets (Q: Mar. 2025 )-Operating Liabilities (Q: Mar. 2025 ))/Total Assets (Q: Dec. 2024 )
=(1356.7-906.9)/1434
=0.31

where

Operating Assets(Q: Mar. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1416.5 - 59.8
=1356.7

Operating Liabilities(Q: Mar. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=906.9 - 0 - 0
=906.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.31 mean?
Biotest AG (HAM:BIO) has a Scaled Net Operating Assets of 0.31 as of Mar. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Biotest AG and its competitors.
Is Biotest AG's Scaled Net Operating Assets too high?
Biotest AG's current Scaled Net Operating Assets is 0.31. Overall, Biotest AG has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Biotest AG's Scaled Net Operating Assets compare to VRTX and REGN?
Biotest AG's Scaled Net Operating Assets of 0.31 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Biotest AG and its competitors. Biotest AG's current Scaled Net Operating Assets is 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest AG stock overvalued right now?
Biotest AG (HAM:BIO) has a current Scaled Net Operating Assets of 0.31. The current Scaled Net Operating Assets is 0.31. Biotest AG's overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Biotest AG (HAM:BIO), the current Scaled Net Operating Assets is 0.31 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest AG Business Description

Address Landsteinerstrasse 5, PO Box 10 20 40, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The company covers preclinical and clinical development of the preparations, plasma collection, production, as well as marketing and sales.
56GF Score

Get the complete analysis for HAM:BIO

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.00
Price